Another "broad spectrum" cancer drug approved: NICE approves Rozlytrek for all solid tumors used to treat NTRK gene fusion

The National Institutes of Health and Care Excellence ,NICE on Thursday released a draft final guidelines recommending the use of Roche's ALK inhibitor, Rozlytinib, through the Cancer DrugFund(CDF), for adults andchildren with non-therapeutic options, who are 12 years of age and older, with no therapeutic options, andchildren with a solid,-positive combination of rhymaidaas a treatment that is not affected by histological effects, and the drug has been approved to treat all solid tumors with the fusion of NTRK gene mutations, regardless of where the cancer originates in the bodyin the UK, 600-700 people have NTRK gene fusion solid tumors"Despite evidence that Rozlytrk can reduce the size of the solid tumor selicuted NTRK gene, further test data is needed," said Meindert Boysen, director of the NICE Centre for Health Technology AssessmentBoyson added: "This decision is an important step forward in genomics-driven cancer therapyEarlier this year, NICE also recommended the use of Bayer's independent histological treatment drug Vitrakvi (larotrectinib) for similar patients through CDF